API-CAT investigators' decisions on anticoagulation following extended treatment for cancer-associated thrombosis.
Eur Heart J Cardiovasc PharmacotherSep 22, 2026
Isabelle Mahé, Florent Happe, Manuel Monreal et al.
✦ AI-curated · Sources linked
In 30 seconds
The API-CAT trial showed that reduced-dose apixaban was noninferior to full-dose for preventing recurrent venous thromboembolism in cancer patients. This descriptive analysis of 1458 patients examined anticoagulation decisions after study treatment discontinuation. Results indicated that 86.4% continued anticoagulation, with 62.7% on full-dose and 36.9% on reduced-dose therapy.
Key findings
- 86.4% of patients continued anticoagulation after study treatment discontinuation.
- 62.7% of those continuing therapy received full-dose anticoagulation.
- Direct oral anticoagulants were prescribed in 89.6% of cases.
- Treatment decisions varied by timing of discontinuation and physician specialty.
Why it matters
Understanding real-world anticoagulation decisions in cancer patients is crucial for optimizing treatment strategies. The variability in dosing highlights the need for clearer guidelines to ensure safe and effective management of venous thromboembolism in this population.